BioLineRx Ltd.
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
About BioLineRx
Pharmaceutical Preparations, SIC 2834
BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases. Its first approved drug is APHEXDA (motixafortide), a peptide indicated in the United States for stem cell mobilization for autologous transplantation in multiple myeloma patients. Commercialization and development of APHEXDA are handled by partners, including Ayrmid Pharma globally outside Asia and Auspex Bioscience in Asia. In addition, the company develops motixafortide for pancreatic cancer and other solid tumors, and collaborates on the clinical development of GLIX1, an oral small molecule candidate targeting DNA damage response in glioblastoma and other malignancies.
The company's primary executive offices are located in Modi'in, Israel. Commercial distribution rights for its approved product span Asia, the United States, and additional global markets through international licensing partnerships, while development activities and corporate collaborations extend across Israel, Europe, and Asia.
Summary of the business section of BioLineRx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioLineRx Ltd.
- Headquarters
- Modi-In, Israel
- Address
- 2 Hamaayan Street, Modi-In Technology Park ISRAEL
- Phone
- 972-8-642-9100
- Website
- biolinerx.com
- Employees
- 20, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Kesselman & Kesselman, Tel Aviv, Israel
Stock & identifiers
- Ticker
- BLRX
- Exchange
- Nasdaq
- IPO date
- Jul 27, 2011
- Shares outstanding
- 2.61B, Mar 8, 2026
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-40 reverse, Jan 30, 2025; 1-for-15 reverse, Jul 15, 2019
- SEC CIK
- 1498403
- CUSIP
- 09071M304
- ISIN
- US09071M3043
- LEI
- 529900AKIOSC15Y63R18
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Philip A. Serlin | Chief Executive Officer | 5,131,800 |
| Mali Zeevi | Chief Financial Officer | 1,311,000 |
| Shaoyu Yan | Director | – |
| Sandra Panem | Director | – |
| Rami Dar | Director | – |
| Avraham Molcho | Director | – |
| Raphael Hofstein | Director | – |
| Gal Avraham Cohen | Director | – |
| Aharon Schwartz | Director | 3,705,000 |
| Barbara-Jean Anne Bormann-Kennedy | Director | – |
Employees
Headcount reported in annual reports
“As of March 8, 2026, we had 20 full-time employees and 4 part-time”